“The board approved the buyback of 3.43 million equity shares of the Company at a price of Rs 350 per equity share for an aggregate amount not exceeding Rs 1,200 million from the equity shareholders of the Company on a proportionate basis through the "Tender Offer" route,” FDC said in a regulatory filing.
As of December 2017, the promoters held 68.89% stake in FDC. Individual shareholder have 14.16% stake, followed by foreign institutional investors (9.37%) and mutual funds (3.67%).
Meanwhile, the pharmaceuticals company reported a strong 94% jump in net profit at Rs 427 million in December 2017 quarter against Rs 220 million in the corresponding quarter of previous year. Operational revenue grew 13% to Rs 2,488 million from Rs 2,201 million in previous year quarter.
At 09:55 AM; the stock was trading 6% higher at Rs 269 on BSE, as compared to 0.94% rise in the S&P BSE Sensex. A combined 253,257 shares changed hands on the counter on BSE and NSE.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)